NCT07412613 2026-02-27
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso
Phase 3 Not yet recruiting
Akeso
Mirati Therapeutics Inc.
Luye Pharma Group Ltd.
IMGT Co., Ltd.
TransThera Sciences (Nanjing), Inc.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Genfleet Therapeutics (Shanghai) Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.